Internal Medicine Department, Istanbul University Cerrahpaşa Faculty of Medicine, Istanbul, Turkey.
Endocrine. 2010 Oct;38(2):199-205. doi: 10.1007/s12020-010-9373-x. Epub 2010 Jul 11.
We aimed to compare the prevalence of antineutrophil cytoplasmic antibody (ANCA) and its subgroups between on-treatment (with anti-thyroid drugs; propylthiouracil, methimazole) and untreated patients with hyperthyroidism in our unit. Overall 78 consecutive patients were enrolled in the study; 45 patients were on-treatment (female/male 31:14) and 33 were newly diagnosed (female/male 20:13). We have studied ANCA, perinuclear-ANCA (p-ANCA), cytoplasmic-ANCA (c-ANCA), myeloperoxidase-ANCA (mpo-ANCA), and proteinase 3-ANCA (pr3-ANCA) in sera of all the patients. The data about clinical status, laboratory tests, and physical examination and mean duration of treatment in treated group were recorded. There was no statistically significant difference between the two groups for ANCA, c-ANCA, and pr3-ANCA (P=0.13, P=0.07, and P=0.63 respectively). p-ANCA and mpo-ANCA prevalences were significantly higher in on-treatment group than in untreated group (P=0.04 and P=0.01, respectively). The mean duration of treatment was 17 months in on-treatment group. The use of antithyroid drugs (propylthiouracil, methimazole) seems to be correlated with increased prevalence of ANCA. These drugs may especially increase p-ANCA and mpo-ANCA positivity.
我们旨在比较本单位治疗组（用抗甲状腺药物；丙基硫氧嘧啶、甲巯咪唑）和未治疗组甲亢患者抗中性粒细胞胞浆抗体（ANCA）及其亚群的患病率。共有 78 例连续患者入组本研究；45 例为治疗组（女性/男性 31:14），33 例为新诊断（女性/男性 20:13）。我们研究了所有患者血清中的 ANCA、核周型-ANCA（p-ANCA）、细胞质型-ANCA（c-ANCA）、髓过氧化物酶-ANCA（mpo-ANCA）和蛋白酶 3-ANCA（pr3-ANCA）。记录了治疗组的临床状况、实验室检查、体检和平均治疗时间的数据。两组间 ANCA、c-ANCA 和 pr3-ANCA 无统计学差异（P=0.13、P=0.07 和 P=0.63）。治疗组 p-ANCA 和 mpo-ANCA 患病率明显高于未治疗组（P=0.04 和 P=0.01）。治疗组的平均治疗时间为 17 个月。抗甲状腺药物（丙基硫氧嘧啶、甲巯咪唑）的使用似乎与 ANCA 患病率增加有关。这些药物可能特别增加 p-ANCA 和 mpo-ANCA 的阳性率。
